RT Journal Article
SR Electronic
T1 Cytosolic PCNA interacts with S100A8 and controls an inflammatory subset of neutrophils in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.12.22280984
DO 10.1101/2022.10.12.22280984
A1 de Oliveira Formiga, Rodrigo
A1 Pesenti, Lucie
A1 Ladjemi, Maha Zohra
A1 Frachet, Philippe
A1 Andrieu, Muriel
A1 Many, Souganya
A1 Karunanithy, Vaarany
A1 Bailly, Karine
A1 Dhôte, Théo
A1 Castel, Manon
A1 Rousseau, Christophe
A1 Starick, Marick
A1 da Rocha, Edroaldo Lummertz
A1 Lombardi, Emilia Puig
A1 Granger, Vanessa
A1 Chollet-Martin, Sylvie
A1 De Chaisemartin, Luc
A1 Mouthon, Luc
A1 Spiller, Fernando
A1 Hosmalin, Anne
A1 Hurtado-Nedelec, Margarita
A1 Martin, Clémence
A1 Pène, Frédéric
A1 Burgel, Pierre-Regis
A1 Tourneur, Léa
A1 Witko-Sarsat, Véronique
YR 2022
UL http://medrxiv.org/content/early/2022/10/13/2022.10.12.22280984.abstract
AB Neutrophils are key players in the hyperinflammatory response upon SARS-CoV-2 infection. We have previously described that cytosolic proliferating cell nuclear antigen (PCNA) controls neutrophil survival and NADPH oxidase-dependent ROS production. We here show that both PCNA and S100A8 expression and interaction were elevated in neutrophils from patients with COVID-19 compared to healthy donors and this was correlated with disease severity. Increased PCNA expression was accompanied by a decreased apoptosis and increased NADPH-oxidase activity in neutrophils from COVID-19 patients compared to healthy donors. These effects, as well as the interaction between PCNA and S100A8, were potently counteracted by T2 amino alcohol (T2AA), a PCNA inhibitor, demonstrating that the PCNA scaffold orchestrated neutrophil activation. Notably, the interaction between PCNA-S100A8 was more intense in the CD16high-CD62Llow activated neutrophil subset. We propose that PCNA-S100A8 complex acts as potential driver for neutrophil dysregulation in COVID-19 and show for the first time that the PCNA scaffold is a decisive component of both neutrophil activation and heterogeneity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFondation pour la Recherche Medicale Grant EQU202003010155 (VWS) the Investissements Avenir programme ANR-11-IDEX-0005-02 Sorbonne Paris Cite LabEx INFLAMEX (VWS) the French National Research Agency (ANR) with the Grant RA-COVID-19 V5-COVINNATE (MHN) Grant DENDRISEPSIS ANR-17-CE15-0003 (FP) Grant APCOD ANR-17-CE15-0003-01 (FP) the Sao Paulo research Foundation Grant FAPESP-SCRIPPS 15/50387-4 (FS)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individuals hospitalized due to COVID-19 from April 2020 to January 2022 were recruited in Paris, at the Cochin Hospital from the Internal Medicine department (authorization #2019-3677), the Respiratory medicine department (authorization #2020 #A02700-39) and from the Intensive Care Medicine department (authorization #2018 #A01934-51) and at Bichat Hospital from the Intensive Care Medicine department (authorization #2020-715). This study was approved by the Hospital Ethics Committee, according to the Declaration of Helsinki. Each patient gave written informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors